Subungual Splinter Hemorrhages: A Clinical Window to Inhibition of Vascular Endothelial Growth Factor Receptors?
Authors: Caroline Robert, Sandrine Faivre, Eric Raymond, Jean-Pierre Armand, Bernard Escudier
Journal: Annals of Internal Medicine (2005)

Letters16 August 2005Subungual Splinter Hemorrhages: A Clinical Window to Inhibition of Vascular Endothelial Growth Factor Receptors?Caroline Robert, MD, PhD, Sandrine Faivre, Eric Raymond, Jean-Pierre Armand, and Bernard EscudierCaroline Robert, MD, PhDFrom Institute Gustave Roussy, 94800 Villejuif Cedex, France., Sandrine FaivreFrom Institute Gustave Roussy, 94800 Villejuif Cedex, France., Eric RaymondFrom Institute Gustave Roussy, 94800 Villejuif Cedex, France., Jean-Pierre ArmandFrom Institute Gustave Roussy, 94800 Villejuif Cedex, France., and Bernard EscudierFrom Institute Gustave Roussy, 94800 Villejuif Cedex, France.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-143-4-200508160-00021 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Background: Over the past few years, cancer therapy has been profoundly changed by the development of drugs targeting specific kinases involved in the proliferation of tumor or endothelial cells. Some kinase inhibitors exhibit antiangiogenic activity by targeting vascular endothelial growth factor receptors (VEGFRs).Objective: We report the results of tests of 2 such inhibitors: SU11248 (Pfizer, New York, New York), which inhibits VEGFR-2, platelet-derived growth factor receptor (PDGFR), KIT, and flt3, and BAY 439006 (Onyx Pharmaceuticals, Emeryville, California, and Bayer, Leverkusen, Germany), which targets VEGFR-2 and VEGFR-3, PDGFR, and RAF gene products.Methods and Findings: In a ...References1. Robert C, Spatz A, Faivre S, Armand JP, Raymond E. Tyrosine kinase inhibition and grey hair [Letter]. Lancet. 2003;361:1056. [PMID: 12660081] CrossrefMedlineGoogle Scholar2. Young JB, Will EJ, Mulley GP. Splinter haemorrhages: facts and fiction. J R Coll Physicians Lond. 1988;22:240-3. [PMID: 3230540] MedlineGoogle Scholar3. Mujic F, Lloyd M, Cuadrado MJ, Khamashta MA, Hughes GR. Prevalence and clinical significance of subungual splinter haemorrhages in patients with the antiphospholipid syndrome. Clin Exp Rheumatol. 1995;13:327-31. [PMID: 7554559] MedlineGoogle Scholar4. Monk BE. The prevalence of splinter haemorrhages. Br J Dermatol. 1980;103:183-5. [PMID: 7426414] CrossrefMedlineGoogle Scholar5. Perez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, et al. Determinants of tumor response and survival with erlotinib in patients with non–small-cell lung cancer. J Clin Oncol. 2004;22:3238-47. [PMID: 15310767] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Institute Gustave Roussy, 94800 Villejuif Cedex, France.Disclosures: None disclosed. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byNail changes with chemotherapeutic agents and targeted therapiesAnticancer TherapiesPlatelet function is disturbed by the angiogenesis inhibitors sunitinib and sorafenib, but unaffected by bevacizumabNail Reactions to Anticancer TherapiesDermatologic Side Effects of Systemic Targeted Anticancer TherapyToxicidad podológica de los tratamientos antineoplásicosNail toxicities induced by systemic anticancer treatmentsSorafenib-Associated Facial Acneiform EruptionCutaneous manifestations of anti-angiogenic therapy in oncology: Review with focus on VEGF inhibitorsAn overview of management of drug-induced hair and nail disordersNail Abnormalities in Oncology PracticeSmall Molecule Multikinase InhibitorsAn apoptosis-homing peptide-conjugated low molecular weight heparin-taurocholate conjugate with antitumor propertiesDermatologic Side Effects of Systemic Anticancer TherapyAntiangiogenic treatments and mechanisms of action in renal cell carcinomaThe Nail in Systemic DiseaseAdvances in the Management of Cutaneous Toxicities of Targeted TherapiesDiscovery of Sunitinib as a Multitarget Treatment of CancerSkin Tumors Induced by Sorafenib; Paradoxic RAS–RAF Pathway Activation and Oncogenic Mutations of HRAS , TP53 , and TGFBR1Sunitinib in advanced pancreatic neuroendocrine tumors: latest evidence and clinical potentialGestion des effets secondaires des thérapies ciblées dans le cancer du rein : thérapies ciblées et effets secondaires dermatologiquesCutaneous toxicities of the multikinase inhibitors sorafenib and sunitinibRAF inhibition and induction of cutaneous squamous cell carcinomaChallenges and Successes in Developing Effective Anti-angiogenic AgentsClinical Guideline for the Diagnosis and Treatment of Cardiovascular InfectionsOptimizing the Use of Sunitinib in Metastatic Renal Cell Carcinoma: An Update From Clinical PracticeAcral lesions in tuberous sclerosis complex: Insights into pathogenesisTargeted therapies in the treatment of GIST: Adverse events and maximising the benefits of sunitinib through proactive therapy managementNail Toxicity Induced by Cancer ChemotherapyBlackberry-induced hand-foot skin reaction to sunitinibPolyproline-type helical-structured low-molecular weight heparin (LMWH)-taurocholate conjugate as a new angiogenesis inhibitorSorafenib-induced erythema multiforme in metastatic renal cell carcinomaToxicité cutanée induite par les thérapies ciblées anti-angiogéniquesEffets cutanés des nouvelles molécules utilisées en cancérologieMode of action and clinical impact of VEGF signaling inhibitorsDermatologic symptoms associated with the multikinase inhibitor sorafenibAntiangiogenic Drugs: Current Knowledge and New Approaches to Cancer TherapyDermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinibMatched case-control phase 2 study to evaluate the use of a frozen sock to prevent docetaxel-induced onycholysis and cutaneous toxicity of the footChemotherapeutic agents and the skin: An updateEffets secondaires cutanés du sorafenib et du sunitinibInhibiteurs de tyrosine kinase du VEGFR: modalités ďadministration et toxicitésEffets secondaires cutanés des nouvelles molécules anticancéreuses : focus sur les molécules ciblant les récepteurs tyrosine kinase et le récepteur à l'EGFCutaneous Reactions Related to Systemic Immunomodulators and Targeted TherapeuticsTargeted therapies for kidney cancer in urologic practiceTyrosine Kinase Inhibitors and Anti-Angiogenic Therapies in Kidney CancerPossible molecular mechanisms involved in the toxicity of angiogenesis inhibitionSunitinib: From Rational Design to Clinical EfficacySorafenib for the Treatment of Advanced Renal Cell CarcinomaNon-Rash Skin Toxicities Associated with Novel Targeted TherapiesSorafenibSorafenib for the Treatment of Renal Cell CarcinomaSafety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With CancerComment gérer au mieux la toxicité des traitements antiangiogéniques? 16 August 2005Volume 143, Issue 4Page: 313-314KeywordsCapillariesDrugsEndocarditisHemorrhageKinase inhibitorsMitral stenosisRashesRheumatoid arthritisTherapeutic drug monitoringVascular endothelial growth factor ePublished: 16 August 2005 Issue Published: 16 August 2005 Copyright & PermissionsCopyright © 2005 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...